The drugmaker is currently gauging interest from potential buyers. The women’s health division may draw bids from both private equity firms and rival pharma companies, people familiar with the matter told the publication.
Pfizer’s women’s health unit includes products such as menopause treatments Premarin, Prempro and Premphase.
By selling off the unit, Pfizer would become the latest drugmaker to sell its women’s health lines as it shifts resources to other parts of its portfolio. Both Allergan and Teva Pharmaceuticals have announced plans to wind down their women’s health units.
Read the full report here.
More articles on pharmacy:
Pfizer will likely hike drug prices come January
Novartis scraps 90 drug research programs
J&J loses patent fight over prostate cancer blockbuster
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.